Galectin-3 levels are a crucial biomarker for various diseases, and its regulation is influenced by a combination of genetic and environmental factors. Understanding these factors may provide a better insight into the pathogenesis of diseases in which galectin-3 is involved and open new avenues for the development of targeted therapies.
Galectin-3 levels
Galectin-3 is a multifunctional protein that belongs to the lectin family, proteins that bind specifically to carbohydrates. This protein is of particular interest in the biomedical field due to its involvement in various physiological and pathological processes. Galectin-3 levels in the body are an important biomarker for a variety of conditions, including cardiovascular disease, fibrosis, cancer and chronic inflammation. Galectin-3 plays a crucial role in the regulation of innate immunity, apoptosis, cell adhesion, cell proliferation and differentiation. Therefore, measurement of its levels can provide valuable information about health status and disease progression.
Galectin-3 levels can be modulated by a number of both endogenous and exogenous factors. Endogenous factors include the presence of inflammation and tissue damage. During inflammatory processes, macrophages and other types of immune cells can release galectin-3, which contributes to tissue repair and modulation of the immune response. Fibrosis is another process in which galectin-3 plays a prominent role, as it facilitates collagen accumulation and tissue remodeling, which is crucial in diseases such as liver fibrosis and cardiac fibrosis. Among exogenous factors, lifestyle habits such as diet, exercise and alcohol consumption can influence galectin-3 levels. Oxidative stress and exposure to environmental toxins can also modify the expression of this protein.
Number of observed variants
13.5 million variants
Number of risk loci
18 loci
Genes analyzed
Bibliography
Folkersen L., Gustaffson S., et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nature Metabolism, 16 Oct 2020, 2(10):1135-1148.
Blanda V., Marcello U.B., et al. Galectin-3 in cardiovascular diseases. Int. J. Mol. Sci. 2020, 21(23), 9232.
